¿Has olvidado la contraseña?

  • Código edición papel
    • Si tienes la 8ª edición de la Guía Terapéutica en papel, puedes acceder a la web con el código personalizado que aparece en ella. No son válidos los códigos de ediciones anteriores. Regístrate
  • Suscripción online
    • ¿No tienes la edición en papel? Puedes suscribirte sin necesidad de código. Suscríbete

Para cualquier consulta o incidencia, puedes contactarnos a través del correo guiaterapeutica@semfyc.es

Quiero darme de baja
Volver a bibliografía

Enfermedades infecciosas no incluidas en las otras unidades

  • BMJ Publishing Group. Evidencia clínica. 2 ed. Bogotá: Legis; 2003.
  • CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007;56:332-6.
  • Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59(N.RR-12):1-95.
  • Grupo de expertos de GESIDA y del Plan Nacional sobre el Sida. Documento de consenso sobre las infecciones de transmisión sexual en personas con infección por el VIH (Septiembre 2010). Disponible en: http://www.msps.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/docConsensoITSSept10.pdf
  • Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis 2006;42:1075-80.
  • Hellín T, Rodríguez A, Ribera E. Enfermedades de transmisión sexual. Protocolos clínicos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica [en línea]. [Consulta realizada el 22 Feb 2004]. Disponible en: http://www.seimc.org/protocolos/clinicos/index.htm.
  • Mensa J, Gatell J, García-Sánchez J, Letang E, López-Suñe E. Guía de Terapéutica Antimicrobiana 2010. 20 ed. Barcelona: Masson; 2010.
  • National Guidelines on the Management of Suspected Sexually Transmitted Infections in Children and Young People 2010. BASHH Clinical Effectiveness Group. Disponible en: http://www.bashh.org/guidelines
  • SemFYC. Infecciones agudas en el adulto. FMC 1998;5(Supl 9):1-242.

Brucelosis

  • Everett ED. Brucellosis in children. UpToDate, 2007. Disponible en: http://patients.uptodate.com/topic.asp?file=pedi_id/7228&title=Brucellosis.
  • Ford N, Shubber Z, Jao J, Abrams EJ, Frigati L, Mofenson L. Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):512-21. doi: 10.1097/QAI.0000000000000211. PMID: 24853309; PMCID: PMC4331013.
  • Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011 Nov 8;183(16):1851-8. doi: 10.1503/cmaj.111152. Epub 2011 Oct 11. PMID: 21989472; PMCID: PMC3216436.
  • Huang S, Xu J, Wang H, Li Z, Song R, Zhang Y, Lu M, Han X, Ma T, Wang Y, Hao J, Song S, Zhen Q, Shui T. Updated therapeutic options for human brucellosis: A systematic review and network meta-analysis of randomized controlled trials. PLoS Negl Trop Dis. 2024 Aug 22;18(8):e0012405. doi: 10.1371/journal.pntd.0012405. PMID: 39172763; PMCID: PMC11340890.
  • Keramat F, Ranjbar M, Mamani M, Hashemi SH, Zeraati F. A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. Trop Doct. 2009 Oct;39(4):207-10.
  • Roushan MR, Amiri MJ, Janmohammadi N, Hadad MS, Javanian M, Baiani M, et al. Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial. J Antimicrob Chemother. 2010 May;65(5):1028-35. Epub 2010 Mar 9.
  • Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005;352:2325-36.
  • Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007;4(12):e317.
  • Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008;336:678-9.
  • Solera J. Update on brucellosis: therapeutic challenges. Int J Antimicrob Agents. 2010;36(Suppl 1): S18-20.
  • Trimetoprima/sulfametoxazol 160/800 mg comprimidos [ficha técnica]. Agencia Española de Medicamentos y Productos Sanitarios; 2025.

Chancroide

  • Hicks Ch. Chancroid. En: UpToDate, Issue 1, 2008.
  • Holland-Hall C. Sexually transmitted infections: screening, syndromes, and symptoms. Prim Care. 2006;33:433-54.
  • Kaliaperumal K. Recent advances in management of genital ulcer disease and anogenital warts. Dermatol Ther 2008;21:196-204.
  • Lewis DA, Ison CA. Chancroid. Sex Transm Infect 2006;82(Suppl 4):iv19-20.
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. 2010;59:RR12.

Enfermedades de transmisión sexual (en agresiones sexuales)

  • Clinical Effectiveness Group. Group 2002 National Guidelines on the Management of Adult Victims of Sexual Assault. Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases [en línea]. [Consulta realizada el 22 Feb 2004]. Disponible en: http://www.guideline.gov/summary/summary.aspx?doc_id=3050.
  • Cybulska B, Forster G, Welch J, Lacey H, Rogstad K, Lazaro N. Clinical Effectiveness Group British Association for Sexual Health and HIV. UK National Guidelines on The Management of Adult and Adolescent Complainants of Sexual Assault 2011. London (UK): British Association for Sexual Health and HIV; 2011.
  • Fisher M, Benn P, Evans B. Clinical Effectiveness Group (British Association for Sexual Health and HlV). UK Guideline for the use of post- exposure prophylaxis for HIV following sexual exposure. Int J STD & AIDS. 2006;17:81-92.
  • Forrest L. Patient initiated aggression and violence in Australian general practice. Aust Fam Physician. 2010;39:323-6.
  • Hack JB, Hecht C. Emergency physicians' patterns of treatment for presumed gonorrhea and chlamydia in women: one center's practice. J Emerg Med 2008;31.
  • Heke S, Forster G, D'Ardenne P. Risk identification and management of adults following acute sexual assault. Sexual and Relationship Therapy. 2009;24:4-15.
  • Kaufman M and the Committee on Adolescence. Care of the Adolescent Sexual Assault Victim. Pediatrics. 2008;122:462-70.
  • Recomendaciones de la SPNS/GESIDA/AEP/ CEEISCAT/SEMP sobre la profilaxis postexposición frente al VIH, VHB y VHC en adultos y niños (Enero 2008). Disponible en: http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/Gesida_dcyrc200801_profilaxispostexposicion.pdf
  • Romero L, Huerfano C, Grillo‐Ardila CF. Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No.: CD012492. DOI: 10.1002/14651858.CD012492.pub2. Accessed 12 August 2025.
  • Sapp MV, Vandeven AM. Update on childhood sexual abuse. Curr Opin Pediatr 2005;17:258-6.
  • Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (GeSIDA). (Noviembre de 2024). Documento de consenso diagnóstico y tratamiento de las infecciones de transmisión sexual en adultos, niños y adolescentes.
  • Welch J, Mason F. Rape and sexual assault. BMJ 2007 Jun 2;334(7604):1154-8.
  • Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1.
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59:RR12.

Fiebre botonosa mediterránea

  • Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis — United States. MMWR Recomm Rep 2016;65(No. RR-2):1–44. DOI: http://dx.doi.org/10.15585/mmwr.rr6502a1
  • Botelho-Nevers E, Rovery C, Richet H, Raoult D. Analysis of risk factors for malignant Mediterranean spotted fever indicates that fluoroquinolone treatment has a deleterious effect. J Antimicrob Chemother. 2011;66(8):1821-30.
  • Donovan BJ, Weber DJ, Rublein JC, Raasch RH. Treatment of tick-borne diseases. Ann Pharmacother. 2002 Oct;36(10):1590-7. doi: 10.1345/aph.1C089. PMID: 12243610.
  • Garnier JM, Jurquet AL, Retornaz K, Fournier PE, Minodier P. Pediatric Mediterranean spotted fever. Arch Pediatr. 2009;16(Suppl 2):S93-5.
  • Kallinich T, Haffner D, Niehues T, Huss D, Lainka E, Neudorf U, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007;119:e474.
  • Mensa J, Soriano A. Guía de Terapéutica Antimicrobiana 2024 (ed. rústica). Antares Editorial; 2024.
  • Mert A, Ozaras R, Tabak F, Bilir M, Ozturk R. Mediterranean spotted fever: a review of fifteen cases. J Dermatol 2006;33:103-7.
  • Rosenberg PM, Goldfinger SE. Management of familial Mediterranean fever. UpToDate 2008.

Granuloma inguinal

  • CDC. Workowski KA, Berman SM. Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR 2006;55 (RR11);1-94.
  • Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59(No. RR-12):1-95.
  • Queensland sexual health, Clinical management guidelines 2010. Disponible en: http://www.health.qld.gov.au/sexhealth/documents/cm_guidelines.pdf
  • Richens J. Donovanosis (granuloma inguinale). Sex Transm Infect 2006 Dec;82(Suppl 4):iv21-2. No abstract available.
  • Rosen T, Vandergriff T, Harting M. Antibiotic Use in Sexually Transmissible Diseases. Dermatologic Clinics. 2009;27:1.
  • Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (GeSIDA). (Noviembre de 2024). Documento de consenso diagnóstico y tratamiento de las infecciones de transmisión sexual en adultos, niños y adolescentes.
  • Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1.
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. 2010;59:RR12.

Hepatitis crónica por VHC

  • Agarwal K, Cross TJ, Gore C. Chronic hepatitis C. BMJ 2007;334:54-5.
  • Association E. EASL clinical practical guidelines: Management of alcoholic liver disease. J Hepatol. 2012;57(2):399-420.
  • Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51(4):1176-84.
  • Chopra S, Bisceglie. Treatment of chronic hepatitis C virus infection: Recommendations for adults. UpToDate, 2008.
  • Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006;130:225.
  • Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Hermann E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clinical Gastroenterol Hepatol. 2010;8:884-90.
  • Grupo de Trabajo de Enfermedades Infecciosas de la semFYC. Manual de enfermedades infecciosas en Atención Primaria 4.a edición. Barcelona: Congreso y Ediciones SemFYC; 2017.
    Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2.444-51.
  • Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD004888.
  • Jacobson IM, McHutchinson JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16.
  • Mohsen A, Norris S. Hepatitis C Crónica. Evid Clin Concisa 2006;5:206-8.
  • Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance 200 (2010). Disponible en: http://www.nice.org.uk/nicemedia/live/13180/50856/50856.pdf
  • Pitarch Nácher C, Benítez Camps M. Abordaje de la hipertransaminasemia en Atención Primaria. AMF. 2015; 11 (7): 392-9.
  • Poordad F, McCone J, Bacon BR, et al; SPRINT-2 Investigators. Bocepravir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
  • Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician. 2010;81:1351-7.
  • Wilkins T, Tadkod A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician. 2013;88: 35-42.

Hepatitis vírica aguda

  • Corey KE, Ross AS, Wurcel A, Schulze zur Wiesch J, Kim AY, Lauer GM, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 2006;4:1278-1282.
  • Corey KE, Servoss JC, Casson DR, Kim AY, Robbins GK, Franzini J et al. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol. 2009;30(10):1000.
  • Curry MP, Chopra S. Acute Viral Hepatitis. En: Mandell: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Philadelphia: Churchill Livongstone Elsevier; 2010.
  • Gluud LL. Meta-analyses on viral hepatitis. Infect Dis Clin North Am. 2009;23:315-30.
  • Lorenz R, Endres S. Diagnosis and treatment of acute hepatitis C in adults. UpToDate 2008.
  • Petruff C. Overview of hepatitis A virus infection in adults. UpToDate 2008.
  • Shiffman ML. Management of acute hepatitis B. Clin Liver Dis. 2010 Feb;14(1):75-91; viii-ix.
  • Wilkins T, Zimmerman D, Schade RR. Hepatitis B: diagnosis and treatment. Am Fam Physician. 2010;81:965-72.
  • Wong SN, Lok ASF. Treatment of hepatitis B. Who, when, and how? Arch Intern Med 2006;166:9-12.

Linfogranuloma venéreo

  • 2006 national guideline for the management of lymphogranuloma venereum. British Association for Sexual Health and HIV - Medical Specialty Society. 1999 Aug (revised 2006 May).
  • Collins L, White JA. Lymphogranuloma venereum. BMJ 2006;332:66.
  • Gilleece Y, Sullivan A. Management of sexually transmitted infections in HIV positive individuals. Curr Opin Infect Dis 2005;18:43-7.
  • Jebbari H, Alexander S, Ward H, Evans B, Solomou M, Thornton A, et al. UK LGV Incident Group. Update on lymphogranuloma venereum in the United Kingdom. Sex Transm Infect 2007;83:324-6.
  • Scottish Intercollegiate Guidelines Network. Management of genital Chlamydia trachomatis infection. A national clinical guideline. Disponible en: http://www.sign.ac.uk/pdf/sign109.pdf
  • Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (GeSIDA). (Noviembre de 2024). Documento de consenso diagnóstico y tratamiento de las infecciones de transmisión sexual en adultos, niños y adolescentes.
  • US Centers for Disease Control and Prevention. Drugs for sexually transmitted infections. Treat Guidel Med Lett. 2007;5:81-8.
  • White JA. Manifestations and management of lymphogranuloma venereum. Clin Microbiol Infect. 2009;15:4-10.
  • de Vries HJC, de Barbeyrac B, de Vrieze NHN, Viset JD, White JA, Vall-Mayans M, Unemo M. 2019 European guideline on the management of lymphogranuloma venereum. J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1821-1828. doi: 10.1111/jdv.15729. Epub 2019 Jun 26. PMID: 31243838.
  • Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1.
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. 2010;59:RR12.

Profilaxis del defecto del tubo neural

  • Mahmud M, Mazza D. Preconception care of women with diabetes: a review of current guideline recommendations. BMC Womens Health. 2010;10:5.

Profilaxis primaria y secundaria de VIH/sida para neumonía por P. jiroveci (carinii) y toxoplasmosis

  • Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-81.
  • Brooks JT, Kaplan JE, Masur H. What's new in the 2009 US guidelines for prevention and treatment of opportunistic infections among adults and adolescents with HIV? Top HIV Med. 2009;17:109-14.
  • Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-exposed and infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53(RR-15):1-112. Erratum in: MMWR Morb Mortal Wkly Rep. 2005;54:311.
  • Ford N, Shubber Z, Jao J, Abrams EJ, Frigati L, Mofenson L. Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):512-21. DOI: 10.1097/QAI.0000000000000211. PMID: 24853309; PMCID: PMC4331013.
  • Grupo de trabajo VIH/sida de la semFYC. Infección por el VIH: preguntas y respuestas desde Atención Primaria. Barcelona: semfyc ediciones; 2006
  • Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011 Nov 8;183(16):1851-8. doi: 10.1503/cmaj.111152. Epub 2011 Oct 11. PMID: 21989472; PMCID: PMC3216436.
  • Ibrahim A, Chattaraj A, Iqbal Q, Anjum A, Rehman MEU, Aijaz Z, Nasir F, Ansar S, Zangeneh TT, Iftikhar A. Neumonía por Pneumocystis jiroveci: una revisión del manejo en pacientes inmunocomprometidos con el virus de la inmunodeficiencia humana (VIH) y no VIH. Avicena J Med. 24 de marzo de 2023; 13(1):23-34. doi: 10.1055/s-0043-1764375. PMID: 36969352; PMCID: PMC10038753.
  • Ioannidis J, Wilkinson D. Prevención de las infecciones oportunistas en pacientes con infección por VIH. Evid Clín Concisa 2006;5:653-7.
  • Krajicek BJ, Thomas CF, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med. 2009;30:265-78.
  • Madge S, Matthews P, Singh S, Theobald N. HIV in Primary Care. Disponible en: http://www.medfash.org.uk/publications/documents/HIV_in_Primary_Care.pdf
  • Mofenson LM, Brady MT, Danner SP, Domínguez KL, Hazra R, Handelsman E, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58(RR-11):1-166.
  • Recomendaciones de Gesida/Plan Nacional sobre el sida. Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH en la era del tratamiento antirretroviral de gran actividad [en línea]. [Consulta realizada el 12 Feb 2004]. Disponible en: http://www.msc.es/profesional/preProSalud/sida/pdfs/rec16.pdf
  • Sax PE. Treatment and prevention of Pneumocystis infection in patients with HIV. UpToDate, Connor RF (Ed), Wolters Kluwer. [Consultado el 13 de agosto de 2025].
  • Teshale, EH, Hanson, DL, Wolfe, MI, Brooks JT, Kaplan JE, Bort Z, et al. Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003. Clin Infect Dis 2007;44:879.
  • Tiejten PA, Bartlett JG. Prophylaxis against Pneumocystis carinii (P. jiroveci) in HIV-infected patients. Disponible en: http://www.uptodate.com
  • Trimetoprima/sulfametoxazol 160/800 mg comprimidos [ficha técnica]. Agencia Española de Medicamentos y Productos Sanitarios; 2025.

Quimioprofilaxis de la enfermedad meningocócica


Sífilis


  • Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (GeSIDA). (Noviembre de 2024). Documento de consenso diagnóstico y tratamiento de las infecciones de transmisión sexual en adultos, niños y adolescentes.

Toxoplasmosis en el embarazo


  • Mandelbrot L. Congenital toxoplasmosis: What is the evidence for chemoprophylaxis to prevent fetal infection? Prenat Diagn. 2020 Dec;40(13):1693-1702. doi: 10.1002/pd.5758. Epub 2020 Jun 29. PMID: 32453454.
  • Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard L, Berrebi A, Le Bouar G, Bory JP, Cordier AG, Ville Y, Perrotin F, Jouannic JM, Biquard F, d'Ercole C, Houfflin-Debarge V, Villena I, Thiébaut R; TOXOGEST Study Group. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018 Oct;219(4):386.e1-386.e9. doi: 10.1016/j.ajog.2018.05.031. Epub 2018 Jun 2. PMID: 29870736.
  • SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group; Thiébaut R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet. 2007 Jan 13;369(9556):115-22. doi: 10.1016/S0140-6736(07)60072-5. PMID: 17223474.

Uretritis


  • Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (GeSIDA). (Noviembre de 2024). Documento de consenso diagnóstico y tratamiento de las infecciones de transmisión sexual en adultos, niños y adolescentes
  • Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1. PMID: 34292926; PMCID: PMC8344968.